A Study of r-PA Treating Patients With Acute Ischemic Stroke(RAISE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1412 participants.
Also called NCT05295173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,412 participants
- Sponsor
- Registry
-
NCT05295173
-
- Other papers using this trial's data
- Efficacy and Safety of Reteplase Versus Alteplase in Acute Ischemic Stroke Based on Fibrinogen Levels: The RAISE Trial Subgroup
- Reteplase versus Alteplase for Acute Ischemic Stroke
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05295173. Randomized; no masking; primary purpose treatment. Start 2022-03-21 (actual); primary completion 2023-06-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of r-PA Treating Patients With Acute Ischemic Stroke(RAISE)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Injection of recombinant human tissue plasminogen kinase derivatives
- Intervention (Drug)
- Recombinant human tissue plasminogen activator
- Lead sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
- Collaborator
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05295173- Content hash
df18d88e15b6ad6d76463b96b5573beb6ac05a7179cdc446db7dd7c553319285